 BEDFORD, Mass.--BUSINESS WIRE--- OCUL OCUTX--Ocular Therapeutix, Inc. NASDAQ:OCUL, a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported in-market unit sales of DEXTENZA billable inserts of 6,924 and 9,321 in July and August, respectively, as part of the Companys corporate presentation at the H.C. Wainwright 23rd Annual Global Investment Conference. August units represent the second highe 